Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
4.130
+0.020 (0.49%)
At close: Jan 21, 2025, 4:00 PM
4.250
+0.120 (2.91%)
After-hours: Jan 21, 2025, 4:00 PM EST
Evotec SE Revenue
Evotec SE had revenue of 184.89M EUR in the quarter ending September 30, 2024, a decrease of -5.80%. This brings the company's revenue in the last twelve months to 777.05M, down -5.33% year-over-year. In the year 2023, Evotec SE had annual revenue of 781.43M with 3.99% growth.
Revenue (ttm)
777.05M EUR
Revenue Growth
-5.33%
P/S Ratio
n/a
Revenue / Employee
153,537 EUR
Employees
5,061
Market Cap
1.46B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
EVO News
- 23 days ago - Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
- 5 weeks ago - Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk - Accesswire
- 7 weeks ago - Evotec Announces Change in Management Board - Accesswire
- 2 months ago - Comment on Withdrawn Non-Binding Offer - Accesswire
- 2 months ago - Halozyme withdraws $2.1 bln buyout offer for Evotec - Reuters
- 2 months ago - Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions - PRNewsWire
- 2 months ago - Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec - PRNewsWire
- 2 months ago - Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - Benzinga